Company: CERO
Filing Date: 2025-08-11
Form Type: S-3
Source: 0001213900-25-073849
Chunk: 18

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-11
Form: S-3
Chunk 18
---
 Please also carefully read the section titled “Cautionary Note Regarding Forward-Looking Statements.”

Risks Related to this Offering by the Selling Stockholders

The shares of Common Stock being offered in this prospectus represent a substantial percentage of the outstanding shares of Common Stock, and the sales of such shares, or the perception that these sales could occur, could cause the market price of the Common Stock to decline significantly.

Under this prospectus, the Selling Stockholders can resell up to a
total of 9,615,385 shares of Common Stock. The shares of Common Stock being offered for resale pursuant to this prospectus by the Selling
Stockholders would represent approximately 81.6% of the shares of Common Stock outstanding as of August 1, 2025, assuming and after giving
effect to the issuance of Common Stock upon exercise of all outstanding Common Warrants and Options, including shares reserved pursuant
to the 2024 Plan and 2024 ESPP, and the maximum number of shares of Common Stock issuable upon conversion of all outstanding Preferred
Shares. Given the substantial number of shares of Common Stock being registered pursuant to this prospectus, the sale of such shares,
or the perception in the market of the potential for the sale of a large number of shares, could increase the volatility of the market
price of the Common Stock or result in a significant decline in the public trading price of the Common Stock.

After the registration statement of which this
prospectus forms a part is effective and until such time that it is no longer effective, it will permit the resale of these shares of
Common Stock. The resale, or expected or potential resale, of a substantial number of shares of our Common Stock in the public market
could adversely affect the market price for our Common Stock and make it more difficult for you to sell your holdings at times and prices
that you determine are appropriate. Furthermore, we expect that, because there is a large number of shares of our Common Stock being registered
pursuant to the registration statement of which this prospectus forms a part, the Selling Stockholders thereunder will continue to offer
the securities covered thereby for a significant period of time, the precise duration of which cannot be predicted. Accordingly, the adverse
market and price pressures resulting from an offering pursuant to the registration statement may continue for an extended period of time.
Sales of substantial number of such shares in the public market, including the resale of the shares of Common Stock held by the Selling
Stockholders, could adversely affect